- Home
- BRY vs ATYR Comparison
BRY vs ATYR Comparison
Compare BRY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRY | ATYR |
|---|---|---|
| Founded | 1909 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.1M | 79.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRY | ATYR |
|---|---|---|
| Price | $3.22 | $0.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.00 | ★ $8.75 |
| AVG Volume (30 Days) | 590.5K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $730,290,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $0.64 |
| 52 Week High | $5.09 | $7.29 |
Technical Indicators
Market Signals| Indicator | BRY | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 38.02 | 39.64 |
| Support Level | $3.32 | $0.70 |
| Resistance Level | $3.50 | $0.83 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.17 | 22.26 |
Price Performance
Historical ComparisonAbout BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.